1. World Health Organization. Global Health Estimates 2015 Summary Tables: Global deaths by cause, age and sex, 2000-2015. Geneva: WHO; 2016.
2. World Health Organization. Global Health Sector Strategy on Viral Hepatitis 2016-2021: Towards ending viral hepatitis. Geneva: WHO; 2016. Report No.: WHO/HIV/2016.06.
3. Koopsen J, Van Steenbergen J, Richardus JH, Prins M, Op de Coul ELM, Croes EA, et al. Chronic HBV and HCV infections in the Netherlands: Estimated prevalence in risk groups and the general population. Poster session presented at. EASL, the International Liver Congress; Paris, FranceApr 11-15, 2018.
4. Hofman R, Nusselder WJ, Veldhuijzen IK, Richardus JH. Sterfte aan chronische hepatitis B en C in Nederland. Nederlands tijdschrift voor geneeskunde. 2016;160:D511.
5. David S, Hogenbirk R, Van Steenbergen J, Urbanus A. Meer dan opsporen: Nationaal Hepatitisplan: een strategie voor actie. Bilthoven: RIVM; 2016. Report No.: 2016-0166.
6. Gezondheidsraad. Screening van risicogroepen op hepatitis B en C. Den Haag: Gezondheidsraad; 2016. Report No.: 2016/16.
7. Helsper CW, van Essen GA, Bonten MJM, de Wit NJ. A support programme for primary care leads to substantial improvements in the effectiveness of a public hepatitis C campaign. Family Practice. 2010;27(3):328-32.
8. Helsper CW, Janssen MP, van Essen GA, Croes EA, van der Veen C, de Wit AG, et al. Effectiveness and cost-effectiveness of nationwide campaigns for awareness and case finding of hepatitis C targeted at people who inject drugs and the general population in the Netherlands. International Journal of Drug Policy. 2017;47:117-25.
9. Zuure FR, Davidovich U, Coutinho RA, Kok G, Hoebe CJPA, van den Hoek A, et al. Using Mass Media and the Internet As Tools to Diagnose Hepatitis C Infections in the General Population. American Journal of Preventive Medicine. 2011;40(3):345-52.
10. Van Bentum P, Ter Beest G, Swanink C, Spanier BWMR, C. Heptember: Hepatitis Awareness Maand. RIVM. 2016.
11. Heil J, Hoebe CJPA, Cals JWL, Ter Waarbeek HLG, van Loo IHM, Dukers-Muijrers NHTM. Detecting Hepatitis B and C by Combined Public Health and Primary Care Birth Cohort Testing. Annals of family medicine. 2018;16(1):21-7.
12. Zuure FR, Bouman J, Martens M, Vanhommerig JW, Urbanus AT, Davidovich U, et al. Screening for hepatitis B and C in first-generation Egyptian migrants living in the Netherlands. Liver International. 2013;33(5):727-38.
13. Richter C, Ter Beest G, Gisolf EH, Van Bentum P, Waegemaekers C, Swanink C, et al. Screening for chronic hepatitis B and C in migrants from Afghanistan, Iran, Iraq, the former Soviet Republics, and Vietnam in the Arnhem region, The Netherlands. Epidemiology and Infection. 2014;142(10):2140-6.
14. Grintjes KMANP, Dofferhoff ASM, Stelma F, Koene RPM, Van Crevel R, Van den Muijsenbergh M, et al. Hepatitis C-opsporing onder migranten in Nijmegen (HECOM). Tijdschr Infect. 2014;9(5):126-33.
15. Bil JP, Schrooders PA, Prins M, Kouw PM, Klomp JH, Scholing M, et al. Integrating hepatitis B, hepatitis C and HIV screening into tuberculosis entry screening for migrants in the Netherlands, 2013 to 2015. Eurosurveillance. 2018;23(11):17-00491.
16. Richter C, Beest GT, Sancak I, Aydinly R, Bulbul K, Laetemia-Tomata F, et al. Hepatitis B prevalence in the Turkish population of Arnhem: implications for national screening policy? Epidemiology and Infection. 2012;140(4):724-30.
17. Urbanus AT, van de Laar TJW, van den Hoek A, Zuure FR, Speksnijder AGCL, Baaten GGG, et al. Hepatitis C in the general population of various ethnic origins living in the Netherlands: Should non-Western migrants be screened? Journal of hepatology. 2011;55(6):1207-14.
18. Bouman-Notenboom AJ, Van Diemen AJ, Van Heerwaarden A, Schout C. China onder de Dom. Hepatitis B- en C-screening bij Chinese migranten in Utrecht. Infectieziekten Bulletin. 2012;23(1):19-21.
19. GGD Amsterdam. Verslag met beschrijvende analyses China aan de Amstel. Amsterdam: GGD Amsterdam, Afdeling Infectieziekten; 2012.
20. ZonMW. China in het oosten 2013. Available from: https://www.zonmw.nl/nl/
21. Screening en bewustzijnsbevordering hepatitis B en hepatitis C bij Chinezen in Nederland (2009-2013). Available from: https://www.hepatitisinfo.nl/
22. van den Berg CHSB, Smit C, Bakker M, Geskus RB, Berkhout B, Jurriaans S, et al. Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. European Journal of Epidemiology. 2007;22(3):183-93.
23. van Santen DK, van der Helm JJ, Lindenburg K, Schim van der Loeff M, Prins M. HIV and hepatitis C treatment uptake among people who use drugs participating in the Amsterdam Cohort Studies, 1985–2015. International Journal of Drug Policy. 2017;47:95-101.
24. Beuker RJ, Berns MPH, Watzeels JCM, Hendriks V, De Coster EJM, Van der Tonino-Van der Marel E, et al. Surveillance van HIV-infectie onder injecterende druggebruikers in Nederland: meting Den Haag 2000. Bilthoven: RIVM; 2001. Report No.: 441100015.
25. Lindenburg CEA, Lambers FAE, Urbanus AT, Schinkel J, Jansen PLM, Krol A, et al. Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project. European Journal of Gastroenterology & Hepatology. 2011;23(1).
26. Breemer J, Van der Veen C, Hoogenboezem GE. Voorlichtingscampagne rond hepatitis C gericht op drugsgebruikers. Verslaving. 2009;5(2):61-71.
27. Newsum AM, van Rooijen MS, Kroone M, Bruisten SM, Matser A, Hogewoning A, et al. Stable low hepatitis C virus antibody prevalence among HIV-negative MSM attending the STI outpatient clinic in Amsterdam, 2007 – 2017. Sexually transmitted diseases. 2018.
28. Urbanus AT, Van De Laar TJ, Geskus R, Vanhommerig JW, Van Rooijen MS, Schinkel J, et al. Trends in hepatitis C virus infections among MSM attending a sexually transmitted infection clinic; 1995-2010. AIDS (London, England). 2014;28(5):781-90.
29. Hoornenborg E, Achterbergh RCA, Schim van der Loeff MF, Davidovich U, Hogewoning A, de Vries HJC, et al. MSM starting preexposure prophylaxis are at risk of hepatitis C virus infection. AIDS (London, England). 2017;31(11):1603-10.
30. Urbanus AT, van de Laar TJ, Stolte IG, Schinkel J, Heijman T, Coutinho RA, et al. Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic. AIDS (London, England). 2009;23(12):F1-7.
31. Matser A, Geskus R, Heijman T, Urbanus A, Prins J, de Vries H, et al. O1-S10.04 Lifestyle as marker of Hepatitis C infection in HIV infected MSM in Amsterdam, The Netherlands. Sexually Transmitted Infections. 2011;87(Suppl 1):A49.
32. van Rooijen M, Heijman T, de Vrieze N, Urbanus A, Speksnijder A, van Leeuwen P, et al. Earlier Detection of Hepatitis C Virus Infection Through Routine Hepatitis C Virus Antibody Screening of Human Immunodeficiency Virus-Positive Men Who Have Sex With Men Attending A Sexually Transmitted Infection Outpatient Clinic: A Longitudinal Study. Sexually transmitted diseases. 2016;43(9).
33. Schneeberger PM, Keur I, van Loon AM, Mortier D, de Coul KO, Verschuuren-van Haperen A, et al. The Prevalence and Incidence of Hepatitis C Virus Infections among Dialysis Patients in The Netherlands: A Nationwide Prospective Study. The Journal of infectious diseases. 2000;182(5):1291-9.
34. Posthouwer D, Plug I, Van Der Bom JG, Fischer K, Rosendaal FR, Mauser-Bunschoten EP. Hepatitis C infection among Dutch haemophilia patients: a nationwide cross-sectional study of prevalence and antiviral treatment. Haemophilia. 2005;11(3):270-5.
35. Leemrijse CJ, Bongers M, Nielen M, Devillé W. Hepatitis C in penitentiaire inrichtingen. NIVEL; 2009.
36. Schreuder I, Van Veen MG. Prevalentie van hiv, hepatitis B en hepatitis C bij mannen in detentie in Sittard, 2010. RIVM; 2010. Report No.: 210502001.
37. Logtenberg-Van der Grient H. Van testen tot behandeling: Opsporen van HVC positieve bewoners van Maatschappelijke Opvanghuizen en bezoekers van Inloophuizen in Amsterdam [PowerPoint Presentatie]. Harm Reduction Congres 2018.
38. RIVM. Criteria voor verantwoorde screening Bilthoven: RIVM; 2012. Available from: https://www.rivm.nl/
39. Lambers FAE, Prins M, Thomas X, Molenkamp R, Kwa D, Brinkman K, et al. Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM. AIDS (London, England). 2011;25(17):F21-F7.
40. Ingiliz P, Martin TC, Rodger A, Stellbrink H-J, Mauss S, Boesecke C, et al. HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe. Journal of hepatology. 2017;66(2):282-7.
41. Thomas XV, Grady BPX, Van Der Meer JTM, Ho CK, Vanhommerig JW, Rebers SP, et al. Genetic characterization of multiple hepatitis C virus infections following acute infection in HIV-infected men who have sex with men. AIDS (London, England). 2015;29(17):2287-95.
42. Reactie van A. Russcher (06-07-2017) op: Spruijt AG, Wilting KR, Mithoe GD, Niessen WJ. Opsporen van patiënten met chronische virushepatitis. Nederlands tijdschrift voor geneeskunde. 2016;160:D414.
43. Persoonlijke communicatie dr. JGP Reijnders, MDL-arts HagaZiekenhuis Den Haag. 2018.
44. Persoonlijke communicatie dr. EF Schippers, internist-infectioloog HagaZiekenhuis Den Haag en LUMC Leiden. 2018.
45. Beekmans N, Klemt-Kropp M. Re-evaluation of chronic hepatitis B and hepatitis C patients lost to follow-up: results of the Northern Holland hepatitis retrieval project. Hepatology, Medicine and Policy. 2018;3(1):5.
46. Wevers KVC, Puts G, Waegemaekers C, Hautvast JLA, Tostmann A. Detection and evaluation of chronic hepatitis B and C patients who were lost to medical follow upKirsten Wevers. European Journal of Public Health. 2017;27(suppl_3):ckx187.694-
47. Kracht PAM, Arends JE, van Erpecum KJ, Thijsen SFT, Vlaminckx BJM, Weersink AJL, et al. REtrieval And cure of Chronic Hepatitis C (REACH): Results of micro-elimination in the Utrecht province.Liver International. 2018;0(0).
48. Centrum voor infectieziektenbestrijding. Opsporing en herevaluatie van ooit gediagnosticeerden met chronische hepatitis B en C. Handreiking regionale aanpak. Bilthoven: LCI/RIVM; 2016.
49. van de Laar TJW, Molenkamp R, van den Berg C, Schinkel J, Beld MGHM, Prins M, et al. Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam. Journal of hepatology. 2009;51(4):667-74.
50. Boerekamps A, van den Berk GE, Lauw FN, Leyten EM, van Kasteren ME, van Eeden A, et al. Declining Hepatitis C Virus (HCV) Incidence in Dutch Human Immunodeficiency Virus-Positive Men Who Have Sex With Men After Unrestricted Access to HCV Therapy. Clinical Infectious Diseases. 2018;66(9):1360-5.
51. Terrault NA. Sexual activity as a risk factor for hepatitis C. Hepatology (Baltimore, Md). 2002;36(5 Suppl 1):S99-105.
52. Landelijke Coördinatie Infectieziektenbestrijding. Richtlijn Prikaccidenten. Bilthoven: RIVM; 2006.
53. Joy JB, McCloskey RM, Nguyen T, Liang RH, Khudyakov Y, Olmstead A, et al. Phylogenetic estimation of the temporal spread of hepatitis C genotype 1a in North America: a retrospective phylogenetic study. The Lancet Infectious diseases. 2016;16(6):698-702.
54. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science (New York, NY). 1989;244(4902):359-62.
55. Global status report on blood safety and availability 2016. Geneva: World Health Organization; 2017.
56. Van Ameijden EJC, Coutinho R. Large decline in injecting drug use in Amsterdam, 1986-1998: explanatory mechanisms and determinants of injecting transitions. Journal of Epidemiology and Community Health. 2001;55(5):356-63.
57. Van Laar MW, Van Gestel B, Cruts AAN, Van der Pol PM, Ketelaars APM, Beenakkers EMT, et al. Jaarbericht Nationale Drug Monitor 2017. Trimbos Instituut; 2018. Contract No.: AF1568.
58. Van Den Berg C, Smit C, Van Brussel G, Coutinho R, Prins M. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction (Abingdon, England). 2007;102(9):1454-62.
59. van de Laar TJ, van der Bij AK, Prins M, Bruisten SM, Brinkman K, Ruys TA, et al. Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. The Journal of infectious diseases. 2007;196(2):230-8.
60. Blach S, Zeuzem S, Manns M, Altraif I, Duberg A-S, Muljono DH, et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. The Lancet Gastroenterology & Hepatology. 2017;2(3):161-76.
61. World Health Organization. Global hepatitis report. Geneva; 2017.
62. Koopsen J, Van Steenbergen J, Richardus J, Prins M, Op de Coul ELM, Croes EA, et al. Chronic HBV and HCV infections in the Netherlands: Estimated prevalence in risk groups and the general population. EASL, the International Liver Congress; Apr 11-15; Paris, France2018.
63. RIVM. Hepatitis-tool 2017. Available from: https://www.rivm.nl/
64. Cacoub P, Renou C, Rosenthal E, Cohen P, Loury I, Loustaud-Ratti V, et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d’Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l’Hepatite C. Medicine. 2000;79(1):47-56.
65. Cacoub P, Poynard T, Ghillani P, Charlotte F, Olivi M, Piette JC, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis and rheumatism. 1999;42(10):2204-12.
66. Younossi Z, Park H, Henry L, Adeyemi A, Stepanova M. Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden. Gastroenterology. 2016;150(7):1599-608.
67. Lauletta G, Russi S, Conteduca V, Sansonno L. Hepatitis C Virus Infection and Mixed Cryoglobulinemia. Clinical and Developmental Immunology. 2012;2012:502156.
68. Ramos-Casals M, Zignego AL, Ferri C, Brito-Zeron P, Retamozo S, Casato M, et al. Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. Journal of hepatology. 2017;66(6):1282-99.
69. Rutledge SM, Chung RT, Sise ME. Treatment of hepatitis C virus infection in patients with mixed cryoglobulinemic syndrome and cryoglobulinemic glomerulonephritis. Hemodialysis international International Symposium on Home Hemodialysis. 2018;22 Suppl 1:S81-s96.
70. Cacoub P, Comarmond C, Domont F, Savey L, Desbois AC, Saadoun D. Extrahepatic manifestations of chronic hepatitis C virus infection. Therapeutic Advances in Infectious Disease. 2016;3(1):3-14.
71. Fabiani S, Fallahi P, Ferrari SM, Miccoli M, Antonelli A. Hepatitis C virus infection and development of type 2 diabetes mellitus: Systematic review and meta-analysis of the literature. Reviews in endocrine & metabolic disorders. 2018.
72. Dyal HK, Aguilar M, Bartos G, Holt EW, Bhuket T, Liu B, et al. Diabetes Mellitus Increases Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Virus Patients: A Systematic Review. Digestive diseases and sciences. 2016;61(2):636-45.
73. Harris K, Smith L. Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C. The Annals of pharmacotherapy. 2013;47(10):1348-52.
74. Petta S, Maida M, Macaluso FS, Barbara M, Licata A, Craxì A, et al. Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies. Gastroenterology. 2016;150(1):145-55.e4.
75. Hsu YC, Lin JT, Ho HJ, Kao YH, Huang YT, Hsiao NW, et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology (Baltimore, Md). 2014;59(4):1293-302.
76. Yeoh SW, Holmes ACN, Saling MM, Everall IP, Nicoll AJ. Depression, fatigue and neurocognitive deficits in chronic hepatitis C. Hepatology international. 2018.
77. Westbrook RH, Dusheiko G. Natural history of hepatitis C. Journal of hepatology. 2014;61(1 Suppl):S58-68.
78. Infante-Rivard C, Esnaola S, Villeneuve JP. Clinical and statistical validity of conventional prognostic factors in predicting short-term survival among cirrhotics. Hepatology (Baltimore, Md). 1987;7(4):660-4.
79. Albers I, Hartmann H, Bircher J, Creutzfeldt W. Superiority of the Child-Pugh classification to quantitative liver function tests for assessing prognosis of liver cirrhosis. Scandinavian journal of gastroenterology. 1989;24(3):269-76.
80. Liver EAftSot. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. Journal of hepatology. 2018;69(2):406-60.
81. Scarpellini E, Valenza V, Gabrielli M, Lauritano EC, Perotti G, Merra G, et al. Intestinal permeability in cirrhotic patients with and without spontaneous bacterial peritonitis: is the ring closed? The American journal of gastroenterology. 2010;105(2):323-7.
82. Egerod Israelsen M, Gluud LL, Krag A. Acute kidney injury and hepatorenal syndrome in cirrhosis. Journal of gastroenterology and hepatology. 2015;30(2):236-43.
83. Gines A, Escorsell A, Gines P, Salo J, Jimenez W, Inglada L, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology. 1993;105(1):229-36.
84. Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology (Baltimore, Md). 2014;60(2):715-35.
85. Serste T, Melot C, Francoz C, Durand F, Rautou PE, Valla D, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology (Baltimore, Md). 2010;52(3):1017-22.
86. Facciorusso A, Roy S, Livadas S, Fevrier-Paul A, Wekesa C, Kilic ID, et al. Nonselective Beta-Blockers Do Not Affect Survival in Cirrhotic Patients with Ascites. Digestive diseases and sciences. 2018;63(7):1737-46.
87. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of hepatology. 2018;69(1):182-236.
88. Reig M, Mariño Z, Perelló C, Iñarrairaegui M, Ribeiro A, Lens S, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. Journal of hepatology. 2016;65(4):719 – 26.
89. Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. Journal of hepatology. 2016;65(4):727-33.
90. Waziry R, Hajarizadeh B, Grebely J, Amin J, Law M, Danta M, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. Journal of hepatology. 2017;67(6):1204-12.
91. Liver EAftSot. EASL Clinical Practice Guidelines: Recommendations on Treatment of Hepatitis C 2018. Journal of hepatology. 2018.
92. Vrolijk JM, de Knegt RJ, Veldt BJ, Orlent H, Schalm SW. The treatment of hepatitis C: history, presence and future. The Netherlands journal of medicine. 2004;62(3):76-82.
93. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. The New England journal of medicine. 2011;364(25):2405-16.
94. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for Untreated Chronic HCV Genotype 1 Infection. New England Journal of Medicine. 2011;364(13):1195-206.
95. Spruijt AG, Wilting KR, Mithoe GD, Niessen WJ. Opsporen van patiënten met chronische virushepatitis. Nederlands tijdschrift voor geneeskunde. 2016;160:D414.